샘플 요청 목록

 카트 문의
시장보고서
상품코드
1794638

세계의 진성적혈구증가증 치료제 시장

Polycythemia Vera Drugs
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 272 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

진성적혈구증가증 치료제 세계 시장은 2030년까지 14억 달러에 달할 전망

2024년에 11억 달러로 추정되는 진성적혈구증가증 치료제 세계 시장은 2024-2030년 분석 기간에 CAGR 3.2%로 성장하여 2030년에는 14억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 Dasatinib는 CAGR 2.9%를 기록하며 분석 기간 종료시에는 5억 5,730만 달러에 달할 것으로 예상됩니다. Idelalisib 부문의 성장률은 분석 기간 동안 CAGR 2.5%로 추정됩니다.

미국 시장은 3억 890만 달러로 추정되며, 중국은 CAGR 5.9%로 성장할 것으로 예측되는

미국의 진성적혈구증가증 치료제 시장은 2024년에 3억 890만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 5.9%를 기록하며 2030년까지 2억 6,850만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.3%와 2.4%로 예측됩니다. 유럽에서는 독일이 CAGR 1.8%로 성장할 것으로 예측됩니다.

세계의 진성적혈구증가증 치료제 시장 - 주요 동향과 촉진요인 정리

복제 혈류 표적화 : 새로운 치료법이 베라 다혈증 치료의 전망을 재구성하고 있는 방법

왜 진성적혈구증가증 치료제 개발이 전략적으로 확대되고 있는가?

만성 골수 증식성 신생물(MPN)인 진성적혈구증가증(PV)은 골수에서 적혈구 전구체가 복제적으로 증식하여 적혈구가 과다하게 생성되는 것이 특징입니다. 환자의 대부분은 JAK2 V617F 돌연변이를 가지고 있으며, JAK-STAT 신호전달 경로의 구성적 활성화와 사이토카인 과민증을 초래합니다. 약리학적 개입은 혈전 위험을 줄이고, 혈색소 수치를 조절하며, 가려움증, 피로, 비장 부종 등의 증상 부담을 줄이는 것을 목표로 합니다. 대증요법뿐만 아니라 질병 변형 요법이 임상적으로 중요시되면서 치료법이 확대되고, 혈액종양학에서 진성적혈구증가증 치료제의 역할이 커지고 있습니다. 저위험군 환자에게는 여전히 정맥주사와 저용량 아스피린이 일차적인 관리 수단이지만, 고위험군(60세 이상 또는 혈전성 질환의 병력으로 정의되는 경우)에는 세포 환원 요법이 필요합니다. 하이드록시우레아는 전통적으로 가장 표준적인 세포 환원 치료제였으나, 내성, 불내성 및 장기적인 백혈병 발병 위험에 대한 우려가 커지면서 JAK 억제제, 인터페론 및 현재 연구 중인 새로운 저분자 화합물과 같은 새로운 표적 치료제에 대한 수요가 가속화되고 있습니다.

PV의 치료 알고리즘을 지배하는 약물 종류와 치료 프로토콜은 무엇인가?

하이드록시우레아는 혈액학적 조절과 경구투여의 편리성으로 인해 가장 널리 처방되는 1차 선택약물입니다. 그러나 약 20-25%의 환자가 하이드 록시 우레아에 내성 또는 불내성을 보이기 때문에 2차 선택 약제로의 전환이 요구되고 있습니다. 선택적 JAK1/JAK2 억제제인 룩소리티닙은 히드록시우레아 불응성 PV의 주요 치료제로 등장했습니다. RESPONSE 및 RESPONSE-2 임상시험을 기반으로 승인된 룩소리티닙은 헤마토크릿 수치를 효과적으로 낮추고, 비장 부종을 감소시키며, 삶의 질 지표를 개선하는 효과가 있습니다. 페그인터페론α-2a와 로페그인터페론α-2b를 포함한 인터페론 기반 치료는 클론성 조혈을 표적으로 하여 질병 조절 효과를 나타낼 수 있습니다. 특히 로페그 인터페론은 혈액학적 및 분자학적 관해 달성에서 장기적으로 유망한 결과를 보여 젊은 환자와 화학요법이 필요 없는 요법을 원하는 환자에게 적합한 선택이 될 수 있습니다. 격주 투약 스케줄은 기존 인터페론에 비해 복약 순응도를 높입니다. 아스피린은 혈전 예방을 위해 모든 위험군에서 필수적이며, 저분자 헤파린(LMWH)은 급성 혈전 사건에 사용됩니다. 헵시딘 모방 약물(예: PTG-300)과 히스톤 탈아세틸화효소 억제제 등 새로운 임상시험용 약물은 각각 철분 대사 조절, 골수 증식 촉진 억제 능력에 대해 평가되고 있습니다.

바이오마커를 이용한 전략과 개별화 치료는 PV 관리를 어떻게 변화시킬 것인가?

맞춤의료는 유전체 마커, 혈액 마커, 분자 마커를 치료 방침 결정에 통합하여 PV의 치료 전략을 재구성하고 있습니다. JAK2 돌연변이 부하, 대립유전자 빈도, TET2, ASXL1, DNMT3A와 같은 후생유전학적 조절인자의 동시 돌연변이는 위험도 계층화, 골수섬유증 및 급성 골수성 백혈병(AML)으로의 진행 예측, 치료 효과의 평가에 점점 더 많이 활용되고 있습니다. 정량적 PCR을 기반으로 한 JAK2 V617F 추적에 의한 미세잔존병변(MRD) 모니터링은 특히 인터페론 또는 JAK 억제제 치료 중인 환자들을 대상으로 선진국에서 채택되고 있습니다. MPN-SAF(Myeloproliferative Neoplastic Symptom Assessment Form)와 같은 증상 점수와 혈액학적 파라미터를 함께 사용하여 환자가 보고하는 결과에 따라 치료를 조정하는 데 도움을 주고 있습니다. 원격 증상 추적, 헤마토크릿 원격 모니터링, 의사결정 지원 알고리즘과 같은 디지털 헬스 툴은 동적 용량 증량 및 치료 저항성 조기 식별을 돕습니다. 이러한 도구들은 학계와 지역사회에서 종합적인 PV 관리 프로토콜에 통합되고 있습니다.

세계 진성적혈구증가증 치료제의 성장을 뒷받침하는 주요 요인은 무엇인가?

질환에 대한 인식 증가, 표적 치료의 발전, 분자진단에 대한 접근성 확대, MPN 연구에 대한 투자 증가 등이 진성적혈구증가증 치료제 시장의 성장을 견인하고 있습니다. 주요 촉진요인으로는 PV가 장기적인 관리와 병태생리학적 변화가 필요한 만성 악성 종양이라는 인식이 확산되고 있다는 점을 꼽을 수 있습니다. 이러한 재분류는 특히 젊은 나이에 증상이 있는 환자에서 약물 치료를 조기에 시작하도록 장려하고 있습니다. 룩소리티닙과 로페진타페론이 여러 지역에서 승인 및 급여를 받음에 따라 치료 접근성이 확대되고 있으며, 지속적인 혈액학적 및 증상 조절을 입증하는 실제 임상 증거에 의해 뒷받침되고 있습니다. 또한, 철분 대사, 후생유전학적 이상, 염증 신호전달을 표적으로 하는 새로운 기전의 파이프라인 약물이 혈액내과 전문의와 제약 이해관계자들의 관심을 받고 있습니다. 지역 암 진료 현장의 유전자 검사 인프라가 확대되면서 더 많은 환자들이 정확한 진단을 받고 계층화되어 가고 있습니다. 유럽, 아시아, 라틴아메리카에서는 PV 요법이 국가 암 치료 계획 및 혈액학 가이드라인에 포함되면서 의약품 시장 침투가 진행되고 있습니다. 또한, 병용요법 및 조기 치료를 검토하는 임상시험이 진행 중으로 치료 패러다임의 전환과 시장 성장의 가속화가 기대됩니다. PV가 위험 감소 모델에서 정밀 종양학 프레임워크로 이동함에 따라, 차별화되고, 내구성이 있으며, 내약성이 있는 치료제에 대한 수요가 증가하면서 전문 의료 및 일차 의료 채널 모두에서 새로운 기회가 창출될 것입니다.

부문

약물 유형(Dasatinib, Idelalisib, Givinostat, 기타 유형), 최종사용자(병원·진료소, 외래 수술 센터, 기타 최종사용자)

조사 대상 기업 사례

  • AbbVie Inc.
  • Allarity Therapeutics Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd.
  • Bristol Myers Squibb(Clovis Oncology)
  • Daiichi Sankyo Co., Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Incyte Corporation
  • Ionis Pharmaceuticals Inc.
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • PharmaEssentia Corporation
  • Pfizer Inc.
  • Protagonist Therapeutics Inc.
  • Silence Therapeutics Plc
  • Zai Lab Ltd.

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가가 선별한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.28

Global Polycythemia Vera Drugs Market to Reach US$1.4 Billion by 2030

The global market for Polycythemia Vera Drugs estimated at US$1.1 Billion in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Dasatinib, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$557.3 Million by the end of the analysis period. Growth in the Idelalisib segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$308.9 Million While China is Forecast to Grow at 5.9% CAGR

The Polycythemia Vera Drugs market in the U.S. is estimated at US$308.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$268.5 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Polycythemia Vera Drugs Market - Key Trends & Drivers Summarized

Targeting the Clonal Bloodstream: How Emerging Therapies Are Reshaping the Polycythemia Vera Treatment Landscape

Why Is the Drug Development Landscape for Polycythemia Vera Witnessing Strategic Expansion?

Polycythemia vera (PV), a chronic myeloproliferative neoplasm (MPN), is characterized by clonal proliferation of erythroid precursors in the bone marrow, leading to excessive red blood cell production. The majority of patients harbor JAK2 V617F mutations, resulting in constitutive activation of the JAK-STAT signaling pathway and cytokine hypersensitivity. Pharmacological interventions aim to reduce thrombotic risks, control hematocrit levels, and alleviate symptom burden such as pruritus, fatigue, and splenomegaly. The increasing clinical emphasis on disease-modifying therapies-rather than symptomatic control alone-has expanded the therapeutic landscape and elevated the role of polycythemia vera drugs in hematologic oncology. While phlebotomy and low-dose aspirin remain first-line management tools for low-risk patients, high-risk cases-defined by age over 60 or history of thrombotic events-require cytoreductive therapy. Hydroxyurea has traditionally been the gold-standard cytoreductive agent, but growing concerns over resistance, intolerance, and long-term leukemogenic risk have accelerated the demand for newer targeted therapies such as JAK inhibitors, interferons, and novel small molecules under investigation.

Which Classes of Drugs and Treatment Protocols Are Dominating the PV Therapeutic Algorithm?

Hydroxyurea remains the most widely prescribed first-line cytoreductive therapy due to its hematologic control and oral dosing convenience. However, approximately 20-25% of patients exhibit resistance or intolerance to hydroxyurea, prompting a shift toward second-line options. Ruxolitinib, a selective JAK1/JAK2 inhibitor, has emerged as the leading therapy for hydroxyurea-refractory PV. Approved based on the RESPONSE and RESPONSE-2 clinical trials, ruxolitinib effectively reduces hematocrit levels, shrinks splenomegaly, and improves quality of life metrics. Interferon-based therapies, including pegylated interferon alpha-2a and ropeginterferon alpha-2b, offer potential disease-modifying effects by targeting clonal hematopoiesis. Ropeginterferon, in particular, has shown promising long-term results in achieving hematologic and molecular remissions, making it a viable option for younger patients or those seeking chemotherapy-free regimens. Its biweekly dosing schedule also enhances compliance compared to older interferon variants. Aspirin remains essential in all risk groups for thromboprophylaxis, while low-molecular-weight heparins (LMWH) may be used in acute thrombotic events. Emerging investigational agents, such as hepcidin mimetics (e.g., PTG-300) and histone deacetylase inhibitors, are being evaluated for their ability to regulate iron metabolism and suppress myeloproliferative drive, respectively.

How Are Biomarker-Guided Strategies and Personalized Therapies Transforming PV Management?

Personalized medicine is reshaping PV treatment strategies by integrating genomic, hematologic, and molecular markers into therapeutic decisions. JAK2 mutation burden, allele frequency, and co-mutations in epigenetic regulators such as TET2, ASXL1, and DNMT3A are increasingly used to stratify risk, predict progression to myelofibrosis or acute myeloid leukemia (AML), and assess treatment response. Monitoring minimal residual disease (MRD) through quantitative PCR-based JAK2 V617F tracking is gaining adoption in advanced centers, particularly for patients on interferon or JAK inhibitor therapy. The use of hematologic parameters in conjunction with symptom scores such as MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) is helping tailor therapy to patient-reported outcomes. Digital health tools, including remote symptom tracking, telemonitoring of hematocrit, and decision-support algorithms, are supporting dynamic dose titration and early identification of therapy resistance. These tools are being integrated into comprehensive PV management protocols in academic and community settings.

What Are the Principal Drivers Supporting the Growth of Polycythemia Vera Therapeutics Globally?

The growth in the polycythemia vera drugs market is driven by rising disease awareness, advances in targeted therapies, expanded access to molecular diagnostics, and increasing investments in MPN research. A major driver is the growing recognition of PV as a chronic malignancy requiring long-term management and potential disease modification. This reclassification is prompting earlier initiation of pharmacologic therapy, especially in younger, symptomatic patients. The approval and reimbursement of ruxolitinib and ropeginterferon in multiple geographies are expanding therapeutic access, supported by real-world evidence showing sustained hematologic and symptom control. Furthermore, pipeline agents with novel mechanisms-targeting iron metabolism, epigenetic dysregulation, and inflammatory signaling-are attracting interest from hematology specialists and pharmaceutical stakeholders alike. Expansion of genetic testing infrastructure in community oncology settings is enabling more patients to be accurately diagnosed and stratified. Integration of PV therapy into national cancer plans and hematology guidelines across Europe, Asia, and Latin America is increasing drug market penetration. Additionally, ongoing clinical trials investigating combination regimens and earlier-line therapy are expected to shift treatment paradigms and accelerate market growth. As PV transitions from a risk-mitigation model to a precision oncology framework, the demand for differentiated, durable, and tolerable therapies will intensify-creating new opportunities across both specialty and primary care oncology channels.

SCOPE OF STUDY:

The report analyzes the Polycythemia Vera Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Dasatinib, Idelalisib, Givinostat, Other Types); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Allarity Therapeutics Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd.
  • Bristol Myers Squibb (Clovis Oncology)
  • Daiichi Sankyo Co., Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Incyte Corporation
  • Ionis Pharmaceuticals Inc.
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • PharmaEssentia Corporation
  • Pfizer Inc.
  • Protagonist Therapeutics Inc.
  • Silence Therapeutics Plc
  • Zai Lab Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Polycythemia Vera Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Myeloproliferative Disorders Expands Addressable Market for Polycythemia Vera Drugs
    • Increased JAK2 Mutation Testing Drives Early Diagnosis and Treatment Initiation
    • Development of Next-Generation JAK Inhibitors Strengthens Business Case for Targeted Therapy
    • Growing Focus on Cytoreductive Therapies Spurs Demand for Combination Treatment Regimens
    • Regulatory Approvals of Novel Agents Accelerate Product Launches and Market Penetration
    • Expansion of Hematology and Oncology Centers Enhances Treatment Accessibility
    • Real-World Evidence Studies and Longitudinal Registries Promote Treatment Optimization
    • Government Incentives for Orphan Drugs Drive Innovation in Rare Disease Therapeutics
    • Rising Patient Awareness of Blood Cancer Symptoms Spurs Early Clinical Consultation
    • Increased Reimbursement Support for Specialty Oncology Drugs Drives Adoption Rates
    • Advancements in Molecular Profiling Throw the Spotlight on Personalized Therapeutic Pathways
    • Ongoing Clinical Trials in Combination Therapies Strengthen Pipeline Diversity
    • Collaborations Between Biotech Firms and Academic Institutions Fuel Drug Development
    • Pharmacovigilance and Post-Marketing Surveillance Mandates Enhance Drug Safety Framework
    • Rising Use of Phlebotomy and Hydroxyurea Creates Baseline Demand for Maintenance Therapies
    • Patient-Centric Drug Delivery Models Generate Interest in Oral and Subcutaneous Formulations
    • Adoption of Telemedicine and e-Prescriptions Sustains Drug Access in Remote Regions
    • Expansion of Patient Support Programs by Pharma Companies Promotes Adherence
    • Increasing Investment in Rare Hematological Disorders Unlocks Long-Term Market Potential
    • Regulatory Harmonization in Emerging Markets Facilitates Global Access to New Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Polycythemia Vera Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Polycythemia Vera Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Polycythemia Vera Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Dasatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Dasatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Dasatinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Idelalisib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Idelalisib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Idelalisib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Givinostat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Givinostat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Givinostat by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Polycythemia Vera Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Polycythemia Vera Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Polycythemia Vera Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Polycythemia Vera Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Polycythemia Vera Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Polycythemia Vera Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Polycythemia Vera Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Polycythemia Vera Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Polycythemia Vera Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Polycythemia Vera Drugs by Drug Type - Dasatinib, Idelalisib, Givinostat and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Polycythemia Vera Drugs by Drug Type - Percentage Breakdown of Value Sales for Dasatinib, Idelalisib, Givinostat and Other Types for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Polycythemia Vera Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Polycythemia Vera Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제